Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...
Verve Therapeutics’ $306 Million IPO
Arya Sciences Acquisition Corp III’s Merger with Nautilus Biotechnology
Wilson Sonsini Goodrich & Rosati, P.C. advised Nautilus Biotechnology, while Kirkland & Ellis LLP, working alongside Ogier, advised Arya III on the deal. Latham & Watkins...